文献速递白血病造血干细胞移植与细胞治疗

维奈克拉联合阿扎胞苷加或不加高三尖杉酯碱桥接异基因造血细胞移植治疗复发/难治性急性髓系白血病:多中心队列研究

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study.
PubMed 文献 · Br J Haematol · 2025-05-21

本研究纳入350例接受维奈克拉联合阿扎胞苷(VA)或VA联合高三尖杉酯碱(VAH)方案挽救治疗的复发/难治性急性髓系白血病患者,VAH组综合完全缓解率高于VA组(69.9% vs 46.1%)。105例患者后续接受异基因造血干细胞移植,中位移植后随访37.2个月,VAH组3年复发累积发生率低于VA组(19.7% vs 43.2%),3年总生存率和无事件生存率均高于VA组。结论认为VAH方案是桥接移植的有效且安全的挽救治疗。

要点

  • VAH组综合完全缓解率69.9%,高于VA组的46.1%。
  • 移植后VAH组3年复发累积发生率19.7%,低于VA组的43.2%。
  • VAH组3年总生存率82.0%、无事件生存率70.5%,均高于VA组。

核心结论

  • 与VA方案相比,VAH方案是复发/难治性急性髓系白血病患者桥接异基因造血干细胞移植的有效且安全的挽救治疗。

研究设计与样本

  • 多中心队列研究,纳入350例接受VA或VAH方案挽救治疗的复发/难治性急性髓系白血病患者,其中105例接受异基因造血干细胞移植,中位移植后随访37.2个月。

主要发现

  • VAH组综合完全缓解率为69.9%,VA组为46.1%。
  • 移植后3年移植相关死亡率VA组为18.2%,VAH组为9.8%。
  • 移植后3年复发累积发生率VAH组为19.7%,VA组为43.2%。
  • 移植后3年总生存率VAH组为82.0%,VA组为59.1%;3年无事件生存率VAH组为70.5%,VA组为38.6%。
  • 多因素分析显示VAH方案和移植时MRD阴性是复发的保护因素(HR=0.427和HR=0.368),也是无事件生存的保护因素(HR=0.469和HR=0.384)。

临床怎么用

  • 作者认为VAH方案可作为复发/难治性急性髓系白血病患者桥接异基因造血干细胞移植的有效且安全的挽救治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The appropriate salvage regimen followed by allogeneic haematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory (R/R) acute myeloid leukaemia (AML) patients remains unclear. Three hundred and fifty R/R AML patients receiving venetoclax and azacitidine (VA) regimen or VA plus homoharringtonine (VAH) regimen as salvage therapy were enrolled in this study, with a higher composite complete remission rate in the VAH group (69.9%) than in the VA group (46.1%). A total of 105 patients underwent allo-HSCT, with a median follow-up post-transplantation of 37.2 months. The 3-year cumulative incidence of transplant-related mortality was 18.2% in the VA group and 9.8% in the VAH group. The 3-year cumulative incidence of relapse was lower in the VAH group (19.7%) than in the VA group (43.2%). The 3-year overall survival and event-free survival (EFS) were 82.0% and 70.5%, respectively, in the VAH group, which were higher than 59.1% and 38.6%, respectively, in the VA group. Multivariate analysis revealed the VAH regimen and MRD-negative at transplantation were protective factors for relapse (HR = 0.427 and HR = 0.368) and EFS (HR = 0.469 and HR = 0.384). In conclusion, the VAH regimen is an effective and safe salvage therapy bridge to allo-HSCT for R/R AML patients compared with the VA regimen.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ye Y, Liu X, Dai H, et al. Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study. Br J Haematol. 2025. PMID: 40399765. doi:10.1111/bjh.20147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。